ImmunityBio company profile
Company profile
ImmunityBio has 684 employees and is headquartered in San Diego, United States.
Headquartered in San Diego, California, and in existence since 2014, ImmunityBio develops immunotherapies meant to strengthen the body's own immune response against cancer and infectious diseases. Its development platforms cover fusion proteins built on cytokines, DNA-based and viral vector vaccines, and cell therapies, and its clinical programs address both liquid and solid tumors. Its lead product, Anktiva, holds FDA approval and is used alongside BCG in adults with bladder cancer that no longer responds to BCG, a non-muscle invasive form that includes carcinoma in situ. Other pipeline assets include 3M-052, a synthetic TLR7/8 agonist. Collaborations involve the National Cancer Institute, Serum Institute of India and BeOne Medicines, and licenses come from 3M Innovative Properties Company and Access to Advanced Health Institute.
In the fiscal year ended December 2025, revenue reached USD 113.3 million and the net loss was USD 351.4 million. Of total revenue, 99.8% came from the United States and 0.2% from Europe. The company employed 684 people at its headquarters in San Diego.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 3530 John Hopkins Court, 92121, San Diego
- Employees
- 684
- Chief executive
- Richard Adcock
- Founded
- 2014
- Fiscal year
- January - December
- Listing
- IBRX · NASDAQ
- Currency
- USD
- ISIN
- US45256X1037
- Website
- immunitybio.com
ImmunityBio and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| ImmunityBioIBRX | United States | $6.4B | 684 | -150.2% | — |
| Twist BioscienceTWST | United States | $7.4B | 979 | -28.8% | — |
| Corcept TherapeuticsCORT | United States | $9.36B | 730 | 0.8% | 190.2 |
| Madrigal PharmaceuticalsMDGL | United States | $9.93B | 915 | -10.7% | — |
| BioMarin PharmaceuticalBMRN | United States | $11.09B | 3,221 | 16.3% | 146.8 |
| Summit TherapeuticsSMMT | United States | $11.32B | 265 | 0.0% | — |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
